Literature DB >> 26051392

Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis.

Klaus Theede1, Susanne Holck2, Per Ibsen2, Steen Ladelund3, Inge Nordgaard-Lassen4, Anette Mertz Nielsen4.   

Abstract

BACKGROUND & AIMS: In patients with ulcerative colitis (UC), mucosal healing is an important goal of treatment. However, mucosal healing is difficult to determine on the basis of clinical evaluation alone, and endoscopy is uncomfortable and can cause complications. Fecal calprotectin (FC) is a marker of inflammation, and its levels have been associated with disease activity. We investigated the association between level of FC and mucosal healing and clinical disease activity in patients with UC.
METHODS: We performed an observational cross-sectional study of 120 patients with active or inactive UC who underwent sigmoidoscopy at Copenhagen University Hospital Hvidovre from September 2012 through 2014. Endoscopic inflammation was evaluated by using the Mayo Endoscopic Score (MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and histologic inflammatory activity by a slightly modified Harpaz Index, which measures acute inflammation. The Partial Mayo Score was used to measure the clinical disease activity.
RESULTS: A cutoff level of FC of 192 mg/kg identified patients with endoscopic evidence of mucosal healing, which was based on the MES and UCEIS, with positive predictive values of 0.71 and 0.65, respectively; negative predictive values were 0.90 and 0.93, respectively. A cutoff level of 171 mg/kg identified patients with histologic evidence of mucosal healing, with positive predictive value of 0.75 and negative predictive value of 0.90. Levels of FC increased significantly with increases in endoscopic and histologic disease activity. There was high concordance between MES and UCEIS as well as between MES or UCEIS and histologic inflammatory activity. The histologic activity index had an interobserver variation of 4.35%.
CONCLUSIONS: Level of FC identifies patients with UC who have endoscopic and histologic features of mucosal healing and correlates with endoscopic and histologic inflammatory activity. The UCEIS seems to be as accurate as the MES in identifying patients with mucosal healing and as easy to use. The histologic activity index had a high concordance with recognized endoscopic score systems.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IBD; Inflammatory Bowel Disease; Marker; Outcome

Mesh:

Substances:

Year:  2015        PMID: 26051392     DOI: 10.1016/j.cgh.2015.05.038

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  46 in total

Review 1.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

2.  Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.

Authors:  Marcello Cintolo; Giuseppe Costantino; Socrate Pallio; Walter Fries
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

Review 3.  Current best practice for disease activity assessment in IBD.

Authors:  Alissa J Walsh; Robert V Bryant; Simon P L Travis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-01       Impact factor: 46.802

4.  Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.

Authors:  Wing Yan Mak; Anthony Buisson; Michael J Andersen; Donald Lei; Joel Pekow; Russell D Cohen; Stacy A Kahn; Bruno Pereira; David T Rubin
Journal:  Dig Dis Sci       Date:  2018-02-22       Impact factor: 3.199

Review 5.  Histologic scoring indices for evaluation of disease activity in ulcerative colitis.

Authors:  Mahmoud H Mosli; Claire E Parker; Sigrid A Nelson; Kenneth A Baker; John K MacDonald; G Y Zou; Brian G Feagan; Reena Khanna; Barrett G Levesque; Vipul Jairath
Journal:  Cochrane Database Syst Rev       Date:  2017-05-25

6.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

7.  Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study.

Authors:  Talia Zenlea; Eric U Yee; Laura Rosenberg; Marie Boyle; Kavinderjit S Nanda; Jacqueline L Wolf; Kenneth R Falchuk; Adam S Cheifetz; Jeffrey D Goldsmith; Alan C Moss
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

8.  Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.

Authors:  Wei-Chen Lin; Jau-Min Wong; Chien-Chih Tung; Ching-Pin Lin; Jen-Wei Chou; Horng-Yuan Wang; Ming-Jium Shieh; Chin-Hao Chang; Heng-Hsiu Liu; Shu-Chen Wei
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

Review 9.  Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review.

Authors:  T S Chew; J C Mansfield
Journal:  Frontline Gastroenterol       Date:  2016-04-05

10.  Developing a Neural Network Model for a Non-invasive Prediction of Histologic Activity in Inflammatory Bowel Diseases.

Authors:  Iolanda Valentina Popa; Mircea Diculescu; Catalina Mihai; Cristina Cijevschi Prelipcean; Alexandru Burlacu
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.